The article shows U.S. office visits remain at about 70% of pre-pandemic levels, driving high vacancy rates and a flight to newer buildings. It also highlights research linking remote work—not AI—to rising youth unemployment, explores AI uptake among small employer firms versus solopreneurs, and details how emerging biotechs now lead in clinical trials and drug approvals.

• Office visits are stuck at ~70% of pre-COVID levels, pushing vacancy above 14% (a post-2008 high), with tenants flocking to newer (post-2015) buildings while older ones bleed occupants.
• Young workers' higher unemployment traces to remote-work-friendly jobs, not AI exposure—a gap that predates AI's rise, per NY Fed research.
• AI adoption is highest among small firms with employees (26%) versus solo non-employer businesses (14-19%), though high-revenue solopreneurs are the biggest AI power users.
• Emerging pre-commercial biotechs have sharply increased their share of Phase I-III clinical trials over the past decade, cutting into big pharma's former dominance.